Key result
Continuous IV nifekalant terminates 5-day refractory VF in a patient with COVID-19 fulminant myocarditis.
Why the study?
Delayed-onset fulminant myocarditis following COVID-19 infection is rare, and cases complicated by sustained ventricular fibrillation are exceptional.
Does continuous intravenous infusion of nifekalant terminate refractory ventricular fibrillation in a patient with fulminant myocarditis following COVID-19?
Case Report (n=1)
Does continuous intravenous infusion of nifekalant terminate refractory ventricular fibrillation in a patient with fulminant myocarditis following COVID-19?
Nifekalant may be an effective therapeutic option for managing refractory, life-threatening ventricular arrhythmias in patients with COVID-19-associated fulminant myocarditis.
Answers are grounded in this paper and cite their sources.
Should not yet change practice; single case leaves open nifekalant's role in refractory VF complicating fulminant myocarditis.
Fulminant myocarditis (FM) is a life-threatening inflammatory cardiac disease that can rapidly progress to cardiogenic shock or fatal arrhythmias. Delayed-onset FM following coronavirus disease 2019 (COVID-19) infection is rare and cases complicated by sustained ventricular fibrillation (VF) are exceptional. A previously healthy man in his late teens developed dyspnoea and complete atrioventricular block after COVID-19 infection. Echocardiography revealed a left ventricular ejection fraction of 30%. Despite veno-arterial extracorporeal membrane oxygenation and Impella CP support, he developed persistent VF lasting for five days, refractory to amiodarone and repeated defibrillation. Continuous intravenous infusion of nifekalant hydrochloride terminated VF and converted to sinus rhythm. Endomyocardial biopsy demonstrated CD68 + macrophage-predominant inflammation, consistent with COVID-19-associated myocarditis. This case suggests that nifekalant may be a valuable therapeutic option for managing life-threatening ventricular arrhythmias while preserving myocardial contractility in FM following COVID-19 infection.
No takes yet. Share an insight, caveat, or question.
Ojima et al. (2026) conducted a case report in Fulminant myocarditis following COVID-19 (n=1). Nifekalant hydrochloride was evaluated on Termination of ventricular fibrillation. Continuous intravenous infusion of nifekalant successfully terminated 5-day refractory ventricular fibrillation and restored sinus rhythm in a patient with COVID-19-associated fulminant myocarditis.
Synapse has enriched 10 related papers. Consider them for comparative context: